Benzinga | Nov 22, 2021 07:16AM EST

Affimed Announces 100% Objective Response Rate At Highest Dose In Phase 1-2 Study Of Cord Blood-derived Natural Killer Cells Pre-complexed With Innate Cell Engager AFM13 For CD30-positive Lymphomas

* 100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord blood-derived natural killer (cbNK) cells/kg pre-complexed with AFM13

* No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed

* Affimed to host virtual investor event on December 9th to discuss the results